Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest

Main Article Content

Kristian Reich
Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf

Eric L Simpson
Oregon Health & Science University

Richard Langley
Dalhousie University

Richard B Warren
Dermatology Centre, Salford Royal NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, The University of Manchester

Antonio Costanzo
Dermatology Unit Department of Biomedical Sciences, Humanitas University

Hidehisa Saeki
Department of Dermatology, Nippon Medical School

Peter Almgren
Leo Pharma Inc.

Le Gjerum
Leo Pharma Inc.

Anna Carlsson
Leo Pharma Inc.

Melinda Gooderham
Skin Centre for Dermatology

Andreas Pinter
Department of Dermatology, Venereology and Allergology, Goethe-University

Marjolein de Bruin-Weller
University Medical Center Utrecht Department of Dermatology

Andrew Blauvelt
Oregon Medical Research Center

Keywords

tralokinumab, safety, atopic dermatitis, eczema, adverse events

References

1. Nutten S. Ann Nutr Metab. 2015;66(Suppl 1):8-16

2. Weidinger S, Novak N. Lancet. 2016;387:1109-22

3. Popovic B, et al. J Mol Biol. 2017;429:208-19

4. Wollenberg A, et al. Br J Dermatol. 2021;184(3):437-449

5. Silverberg JI, et al. Br J Dermatol. 2021;184(3):450-463

6. Blauvelt A, et al. J Am Acad Dermatol. 2022;S0190-9622(22)02345-3.

Article Sidebar

Poster PDF
Published
Nov 16, 2022
DOI https://doi.org/10.25251/skin.6.supp.79

Article Details

How to Cite
[1]
Reich, K., Simpson, E.L., Langley, R., Warren, R.B., Costanzo, A., Saeki, H., Almgren, P., Gjerum, L., Carlsson, A., Gooderham, M., Pinter, A., de Bruin-Weller, M. and Blauvelt, A. 2022. Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest. SKIN The Journal of Cutaneous Medicine. 6, 6 (Nov. 2022), s79. DOI:https://doi.org/10.25251/skin.6.supp.79.
Issue
Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

<< < 6 7 8 9 10 11 12 13 14 15 > >>